Wanbury Ltd Launches Pediatric Products Aligned with DCGI Guidelines

On March 24, 2026, Wanbury Ltd announced the launch of two new pediatric products under its Coriminic brand. The products, Coriminic CPM Drops and Coriminic NS Nasal Drops, are introduced to align with recent regulatory guidelines issued by the Drugs Controller General of India (DCGI). These guidelines restrict the use of fixed-dose combinations in children under four years due to safety concerns.

The Coriminic CPM Drops contain Chlorpheniramine Maleate and are formulated without a decongestant, specifically for pediatric use. This product addresses the DCGI’s notification limiting fixed-dose cold combinations for young children. The Coriminic NS Nasal Drops offer a non-systemic nasal decongestant solution, providing localized relief from nasal congestion in children. These products are designed to help physicians navigate treatment options within the regulatory boundaries set by the DCGI.

The launch of these products positions Wanbury to capture a share of the INR 861 crore Cold Preparation Liquid market. The company aims to provide safe and regulation-compliant options for pediatric care, aligning with current safety considerations and supporting rational prescribing practices.

This initiative marks a first-of-its-kind approach in India to reposition Chlorpheniramine in a safer, indication-driven format for pediatric use. The launch is part of Wanbury’s strategy to expand its presence in the fast-growing children Cold Preparation Liquid market.

Wanbury Ltd is a pharmaceutical company focused on delivering high-quality, affordable healthcare solutions across key therapeutic segments, including pediatrics. The company prioritizes compliance with regulatory guidelines and aims to provide effective healthcare solutions tailored to specific market needs.